HCW Biologics (HCWB) Net Margin (2022 - 2026)
HCW Biologics' (HCWB) quarterly Net Margin came in at 11340.34% in Q2 2026, up 17311048.0% on a YoY basis from N/an in Q2 2025, and up 11.63% quarter-over-quarter from 12832.14% in Q4 2025.
Powered by 
Analysis
HCW Biologics (HCWB) Net Margin (2022 - 2026) Analysis & Trends
HCW Biologics (HCWB) has reported Net Margin for 5 consecutive years, with 11340.34% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin rose 17311048.0% year-over-year to 11340.34%; the trailing twelve-month figure through Jun 2026 stood at 19203.67% (down 1661269.0% YoY), and the FY2025 full-year result was 41117.24%, down 3994754.0% from the prior year.
- Net Margin climbed to 11340.34% in Q2 2026 per HCWB's latest filing, from 12832.14% in the prior quarter.
- Across five years, Net Margin topped out at 65.99% in Q1 2022 and bottomed at 184450.82% in Q2 2025.
- Historically, Net Margin has averaged 17838.03% across 5 years, with a median of 854.42% in 2024.
- The sharpest annual moves came in 2025 and 2026: Net Margin plunged 18198171 bps in 2025, then soared 17311048 bps in 2026.
- Over 5 years, Net Margin stood at 429.49% in 2022, then tumbled by 89 bps to 813.2% in 2023, then decreased by 5 bps to 854.42% in 2024, then tumbled by 1402 bps to 12832.14% in 2025, then increased by 12 bps to 11340.34% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 11340.34%, 12832.14%, and 29183.24% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | -20,152.98% |
| 10 | HCW Biologics | 3.24 Mn | 2.50 Mn | -93,887.00 | -11,340.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11,340.34% |
| Dec 31, 2025 | -12,832.14% |
| Sep 30, 2025 | -29,183.24% |
| Jun 30, 2025 | -184,450.82% |
| Mar 31, 2025 | -43,862.27% |
| Dec 31, 2024 | -854.42% |
| Sep 30, 2024 | -915.12% |
| Jun 30, 2024 | -2,469.11% |
| Mar 31, 2024 | -665.09% |
| Dec 31, 2023 | -813.20% |
| Sep 30, 2023 | -606.42% |
| Jun 30, 2023 | -739.56% |
| Mar 31, 2023 | -13,022.01% |
| Dec 31, 2022 | -429.49% |
| Sep 30, 2022 | -223.98% |
| Jun 30, 2022 | -773.25% |
| Mar 31, 2022 | -65.99% |